Ranbaxy launches Atorvastatin in Denmark

New Delhi, Feb 13 (UNI) Pharma major Ranbaxy Laboratories Ltd (RLL) has launched the generic Atorvastatin, a cholesterol-lowering drug, in Denmark.

The introduction of Atorvastatin in Denmark is in line with Ranbaxy's Atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable Atorvastatin to patients in Europe and other parts of the world, RLL CEO and Managing Director Malvinder Mohan Singh said.

He further added, ''Generic Atorvastatin will bring significant and immediate cost benefits to the Danish healthcare system.'' The company will continue to actively pursue all options in the EU and other markets in order to bring affordable Atorvastatin to patients around the world.

RLL is an integrated, research-based, pharmaceutical company producing a wide range of quality, affordable generic medicines and serves its customers in over 125 countries.

UNI